Search PubMed⌕ Search

Biomedical subjects

T Palshof

Publications and source records attributed to T Palshof.

At least 37 records · Page 2Linked to original sources
PubMed1982

N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group.

Twenty-nine evaluable patients with extensively pretreated breast cancer received PALA, a new pyrimidine antimetabolite. The drug was given by intravenous infusion over 60 min, at a daily dose of 2.5 g/m2 for 2 consecutive days. Courses were repeated at 2-week intervals and doses were escalated to toxicity. Two objective partial remissions were observed, lasting for 3 and 4.5 months respectively. Toxic effects were dose-related and consisted mainly of mucocutaneous manifestations, i.e., skin rashes, stomatitis, diarrhea, conjunctivitis and corneal ulcerations. Evidence of antitumor potential in far-advanced disease and lack of myelosuppression point to the need for additional trials of PALA in a more favorable selection of patients with breast cancer.

Adult↗
PubMed1981

Histopathological characteristics and oestrogen receptor content in primary breast carcinoma.

159 primary breast carcinomas were examined histologically with regard to grade of anaplasia, cellularity, amount of elastic tissue, and whether they were of ductal or lobular origin. Possible correlations between these variables and the oestrogen receptor (OR)-content were investigated. There was a marked tendency toward a greater number of OR-positive tumors in the group rich in elastosis. A significant correlation between the OR-content and the histological grade was found, whereas there was no correlation between either the OR-content or the grade of anaplasia and the cellularity. Furthermore, the group of tumors that were lobular in derivation had a significantly greater number of OER-positive tumors than the group ductally derived.

Breast Neoplasms↗
PubMed1981

Symposium on the management of early breast cancer (stages I and II). Part II: Clinical experience with treatment methods. 5. Adjuvant endocrine therapy.

A number of trials of adjuvant therapy, including endocrine therapy, for primary breast cancer are in progress. There is an urgent need for increased international cooperation in study design, for defining stratification parameters and coordinating treatment strategy in future adjuvant trials of operable breast cancer. In this way the results of treatment in the different trials will be comparable. On the basis of encouraging clinical and experimental data, adjuvant endocrine therapy is expected to play a major role in the effort to improve the prognosis of primary breast cancer.

Breast Neoplasms↗
PubMed1980

Principles and indications of endocrine treatment of advanced breast cancer.

The numerous trials that have been conducted in advanced breast cancer in premenopausal and postmenopausal women have increased the empiric basis for systemic cytotoxic and endocrine treatment. The treatment results have improved but are still very unsatisfactory, and with all the drugs now at our disposal many questions are still unanswered. For instant this applies to the optimal composition and scheduling of endocrine treatment, cytotoxic treatment, and combinations of these two treatments. During recent years the results of experimental studies have expanded our knowledge of the biology of breast cancer. Future clinical trials should be designed to test and use this information gained from basic research with the aim of improving the rational basis of treatment and obtaining better treatment results in advanced breast cancer.

Aged↗
PubMed1980

Therapeutic effect of tamoxifen related to estrogen receptor level.

Cytoplasmic oestrogen receptor (ER) determinations were performed in 59 postmenopausal patients with metastatic breast cancer. Fifty percent of the patients were found to be ER+. Forty patients were treated with tamoxifen (TAM) and 19 patients were treated with tamoxifen plus medroxyprogesterone acetate (MPA). The response rate of TAM-treated patients was 30% (12/40). Of the 21 ER+ patients, ten (48%) responded to therapy. The ER values of these patients were significantly higher than the ER values of nonresponders (P less than 0.01). No correlation could be found between the ER value and the duration of remission in TAM-treated patients.

Adult↗
PubMed1980

Adjuvant endocrine therapy of breast cancer--a controlled clinical trial of oestrogen and anti-oestrogen: preliminary results of the Copenhagen breast cancer trials.

In an attempt to clarify the value of adjuvant endocrine therapy as an alternative to other treatment modalities, we have started two controlled, prospective, double-blind trials, the Copenhagen Breast Cancer Trials. In these studies postmenopausal women are randomised after primary local treatment to treatment with DES, tamoxifen, or placebo. Premenopausal women are similarly randomised to receive treatment with tamoxifen or placebo. Entry to the trials was closed in March 1978, when 343 patients had entered the studies. The preliminary results indicate that postmenopausal patients with ER+ tumours benefit from adjuvant treatment with tamoxifen. Adjuvant treatment with DES seems to be effective in ER- postmenopausal patients. In postmenopausal patients the ER+ tumors have a lower rate of recurrence. At present these preliminary results do not permit definite conclusions.

Adult↗
PubMed1979

Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women.

Postmenopausal patients, those less than 68 years of age resistant to chemotherapy and those greater than 68 years of age with or without resistance to chemotherapy, entered this trial. Among 101 eligible patients, 46 were randomized to treatment with tamoxifen at a dose of 10 mg 3 times daily and 55 were randomized to treatment with tamoxifen at a dose of 10 mg 3 times daily plus medroxyprogesterone acetate at a dose of 100 mg once daily. Remission (partial plus complete) was obtained in 20 patients (45%) with tamoxifen compared to 14 patients (26%) with tamoxifen plus medroxyprogesterone acetate; however, this difference is not significantly different. The median duration of remission was also not significantly different between the two treatments: 10 months for the single drug compared with 9 months for the combined treatment. Response rates correlated with the presence of estrogen receptor, with no differences between the two treatment groups. Side effects occurred in 12 patients and in only one patient did they cause discontinuation of treatment. In conclusion, these results and theoretic considerations indicate that combined treatment with tamoxifen and medroxyprogesterone acetate is not better than treatment with tamoxifen alone.

Adult↗